retatrutide nonalcoholic steatohepatitis trial significantly improved liver health in patients with non-alcoholic fatty liver disease Retatrutide approval: FDA status, clinical – PDF) Triple hormone receptor agonist

In a randomized placebo-controlled pilot study, researchers examined whether adding phentermine to patients already on liraglutide (a GLP-1 agonist) for one year would produce additional weight loss

Survival rates among those taking diabetes medications were slightly lower compared to the GLP-1 group

Both medicines remain in active clinical development, with phase 2 and phase 3 trials ongoing

Preclinical studies suggested that combining GLP-1, GIP and glucagon receptor activation could yield even greater metabolic benefits than previous therapies

GLP-1Rs are densely expressed in the area postrema in rats (182)

Thats about it